3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
12
Terminated
11
Withdrawn
2
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Myelodysplastic Syndromes
6
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Biphenotypic, Acute
4
Lymphoma, Non-Hodgkin
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Hodgkin Disease
3
Myeloproliferative Disorders
2
Recurrence
1
Primary Myelofibrosis
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Prolymphocytic
1
Leukemia, Monocytic, Acute
1
Leukemia, Lymphoid
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Graft vs Host Disease
1
Burkitt Lymphoma
1
Blastic Plasmacytoid Dendritic Cell Neoplasm
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
ruxolitinib
6
Specimen Handling
6
Stem Cell Transplantation
5
Cyclophosphamide
4
fludarabine
3
Mycophenolic Acid
3
Biopsy
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
Whole-Body Irradiation
2
Tacrolimus
2
Sirolimus
2
Methotrexate
2
Melphalan
2
Hematopoietic Stem Cell Transplantation
2
Blood Component Removal
2
thymoglobulin
1
talazoparib
1
tagraxofusp
1
reparixin
1
poly ICLC
1
piperine
1
pegylated granulocyte colony-stimulating factor
1
merphos
1
letermovir
1
fludarabine phosphate
1
fedratinib
1
demethoxycurcumin
1
daratumumab
1
bomedemstat
1
axatilimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Primary Myelofibrosis
×
Cyclosporine
×
Clear all
NCT04888741
2026-05-05
MoTD
University of Birmingham
Phase 2
Recruiting
400 enrolled